![Christopher Thierry](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Thierry
Presidente presso GENKYOTEX SA.
Profilo
Christopher Thierry has founded Cimpl, Inc. in 2000 where he holds the title of President.
Currently, Mr. Thierry is the Chairman at Calliditas Therapeutics France SAS since 2022.
Posizioni attive di Christopher Thierry
Società | Posizione | Inizio |
---|---|---|
GENKYOTEX SA. | Presidente | 21/01/2022 |
Cimpl, Inc.
![]() Cimpl, Inc. Information Technology ServicesTechnology Services Cimpl, Inc. provides information technology solutions. Its product Cimpl simplifies the task of technology expense management by connecting the complex invoice and usage data of information technology and telecom services. The company was founded by Christopher Thierry and Jeffrey Speak in 2000 and is headquartered in Lachine, Canada. | Fondatore | 01/01/2000 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Cimpl, Inc.
![]() Cimpl, Inc. Information Technology ServicesTechnology Services Cimpl, Inc. provides information technology solutions. Its product Cimpl simplifies the task of technology expense management by connecting the complex invoice and usage data of information technology and telecom services. The company was founded by Christopher Thierry and Jeffrey Speak in 2000 and is headquartered in Lachine, Canada. | Technology Services |
Calliditas Therapeutics France SAS
![]() Calliditas Therapeutics France SAS Pharmaceuticals: MajorHealth Technology Calliditas Therapeutics France SAS is a biopharmaceutical company, which engages in the NOX therapies. Its therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes, such as fibrosis, inflammation, pain processing, cancer development, and eurodegeneration. The firm’s platform enables the identification of orally available small molecules that selectively inhibit specific NOX enzymes. The company was founded in 2006 and is headquartered in Saint-Julien-en-Genevois, France. | Health Technology |
- Borsa valori
- Insiders
- Christopher Thierry